Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention

Breast Cancer Research and Treatment

Volumn 47, Issue 3, 1998, Pages 209-217

  Pollak, Michael N ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Endocrine therapy; GH IGF I axis; Growth hormone; IGF binding proteins; IGFBP proteases; Insulin like growth factor I; Prevention; Risk factors

Indexed keywords

ANTIESTROGEN; GROWTH HORMONE; OCTREOTIDE; PROTEINASE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER PREVENTION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; CLINICAL TRIAL; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; NONHUMAN; PREMENOPAUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMARY NEOPLASMS, EXPERIMENTAL;

EID: 0031985256     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005950916707     Document Type: Article

References (74)

1. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34, 1995
2. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine and Growth Factor Reviews 8:45-62, 1997
3. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80-101, 1994
4. Huynh HT, Nickerson T, Pollak M, Yang XF: Regulation of insulin-like growth factor I receptor gene expression by the pure antiestrogen ICI 182,780. Clin Cancer Res 2:2037-2042, 1996
5. Huynh HT, Yang XF, Pollak M: A role for insulin-like growth factor binding protein 5 in the anti-proliferative action of the antiestrogen ICI 182780. Cell Growth Diff 7:1501-1506, 1996
6. Huynh HT, Yang XF, Pollak M: Estradiol and anti-estrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021, 1996
7. Kleinberg DL, Ruan W, Catanese V, Newman CB, Feldman F: Nonlactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland. Endocrinol 126:3274-3276, 1990
8. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res 45:3415-3443, 1985
9. Yee D: The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 32:85-95, 1994
10. Pollak M, Polychronakos C, Yousefi S, Richard M: Characterization of insulin-like growth factor (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154:326-331, 1988
11. Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type 1 somatomedin receptor. Cancer Res 49:6237-6241, 1989
12. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK: Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418-1423, 1989
13. Yang XF, Beamer W, Huynh HT, Pollak M: Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 56:1509-1511, 1996
14. Jansson JO, Downs TR, Beamer WG, Frohman LA: Receptor-associated resistance to growth hormone-releasing factor in dwarf "little" mice. Science 232:511-512, 1986
15. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE: GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nature Genet 4:227-232, 1993
16. Juul A, Bang P, Hertel N, et al: Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744-752, 1995
17. Pearson OH, Lipsett MB: Effects of hypophysectomy in man. Med Clin North Am 40:773-786, 1956
18. Pearson OH, Manni A, Arafah BM: Antiestrogen treatment of breast cancer: an overview. Cancer Res 42:3424s-3429s, 1982
19. Ray BS, Pearson OH: Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am 12:419-433, 1962
20. Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693-1697, 1990
21. Pollak M: Effects of adjuvant tamoxifen therapy on growth hormone and insulin-like growth factor I (IGF-I) physiology. In: Salmon SE (ed) Adjuvant Therapy of Cancer, VII. J.B. Lippincott, Philadelphia, 1993, pp 43-55
22. Friedl A, Jordan VC, Pollak M: Suppression of serum IGF-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29A:1368-1372, 1993
23. Lien EA, Johannessen DC, Aakvaag A, Lønning PE: Influence of tamoxifen, aminoglutethimide, and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 41:541-543, 1992
24. Lønning PE, Hall K, Aakvaag A, Lien EA: Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52:4719-4723, 1992
25. Reed MJ, Christodoulides A, Koistinen R, Sepp M, Teale JD, Ghilchik MW: The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxy-androstenedione or tamoxifen on plasma concentrations of insulin-Like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer 52:208-212, 1992
26. Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343-1347, 1988
27. Tannenbaum GS, Gurd W, Lapointe M, Pollak M: Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinol 130:3395-3401, 1992
28. Malaab SA, Pollak M, Goodyer CG: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A:788-793, 1992
29. Huynh HT, Tetenes E, Wallace L, Pollak M: In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 53:1727-1730, 1993
30. McGuire WL, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D: Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-I as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336-1341, 1992
31. Pollak M, Ingle J, Suman V, Kugler J: Rationale for combined antiestrogen-somatostatin analogue therapy of breast cancer. In: Salmon SE (ed) Adjuvant Therapy of Cancer, VIII. J.B. Lippincott, Philadelphia, 1997, pp 145-152
32. Pollak M, Schally AV: Mechanism of action of somatostatin analogues as antineoplastic agents. Proc Soc Exp Biol Med (in press)
33. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV: Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91:12298-12302, 1994
34. Lamberts SWJ, Vanderlely AJ, Deherder WW, Hofland LJ: Drug therapy - octreotide. N Engl J Med 334:246-254, 1996
35. Pollak M, Ingle JN, Suman VJ, Kugler JW, Nickerson T, Deroo B: Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast cancer patients by coadministration of the somatostatin analogue octreotide [abstract #1167]. Proc Am Assoc Cancer Res 37:170, 1996
36. Huynh HT, Pollak M: Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 203:253-259, 1994
37. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C: Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 54:6334-6337, 1994
38. Chen WY, Chen NY, Yum J, Washer TE, Kopchick JJ: In vitro and in vivo studies of antagonistic effects of human growth hormone analogues. J Biol Chem 269:15892-15897, 1994
39. Ruan W, Newman C, Kleinberg D: Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 89:10872-10876, 1992
40. Nandi S: Endocrine control of mammary gland development and function in the C3H/He Grg1 mouse. J Natl Cancer Inst 21:1039-1062, 1958
41. Feldman M, Ruan WF, Kleinberg DL: Evidence that the GH receptor mediates differentiation and development of the rat mammary gland [abstract #692]. Proc Endocrine Society, 1992
42. Shiu RPC, Friesen HG: Mechanism of action of prolactin in the control of mammary gland function. Annu Rev Physiol 42:83-96, 1980
43. Goffin V, Shiverick KT, Kelly PA, Martial JA: Sequence relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev 17:385-410, 1996
44. Cohen SM, Ellwein LB: Cell proliferation in carcinogenesis. Science 249:1007-1011, 1990
45. Cohen SM, Ellwein LB: Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51:6493-6505, 1991
46. Kroonsberg C, McCutcheon SN, Siddiqui RA, Mackenzie DD, Blair HT, Ormsby JE, Breier BH, Gluckman PD: Reproductive performance and fetal growth in female mice from lines divergently selected on the basis of plasma IGF-1 concentrations. J Reprod Fertil 87:349-353, 1989
47. Ruggeri BA, Klurfeld DM, Kritchevsky D, Furlanetto RW: Growth factor binding to DMBA-induced mammary tumors from rats subject to chronic caloric restriction. Cancer Res 49:4135-4141, 1989
48. Albanes D: Total calories, body weight, and tumor incidence in mice. Cancer Res 47:1987-1992, 1987
49. Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80-101, 1994
50. Michels KB, Trichopoulos D, Robins JM, Rosner BA, Manson JE, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE, Willett WC: Birthweight as a risk factor for breast cancer. Lancet 348:1542-1546, 1996
51. Osorio M, Torres J, Moya F, Pezzullo J, Salafia C, Baxter R, Schwander J, Fant M: Insulin-like growth factor (IGFs) and IGF binding proteins-1, -2 and -3 in newborn serum: Relationships to fetoplacental growth at term. Early Human Devel 46:15-26, 1996
52. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 335:1363-1367, 1996
53. Hunter DJ, Willett WC: Diet, body size, and breast cancer. Epidemiol Revs 15:110-132, 1993
54. deWaard F, Cornelis JP, Aoki K, Yoshida M: Breast cancer incidence according to weight and height in two cities of the Netherlands and in Aichi prefecture, Japan. Cancer 40:1269-1275, 1977
55. Vatten L, Kvikstad A, Nymoen E: Incidence and mortality of breast cancer related to body height and living conditions during childhood and adolescence. Eur J Cancer 28:128-131, 1992
56. Murata M, Kuno K, Sakamoto G: Epidemiology of family predisposition for breast cancer in Japan. J Natl Cancer Inst 69:1229-1234, 1982
57. Tretli S: Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer 44:23-30, 1989
58. Vatten LJ, Kvinnsland S: Body height and risk of breast cancer. A prospective study of 23,831 Norwegian women. Br J Cancer 61:881-885, 1990
59. Mondina R, Borsellino G, Poma S, Baroni M, Di Nubila B, Sacchi P: Breast carcinoma and skeletal formation. Eur J Cancer 28A:1068-1070, 1992
60. Tornell J, Rymo L, Isaksson OGP: Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. Int J Cancer 49:114-117, 1991
61. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson OGP: High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 43:237-242, 1992
62. Huynh HT, Beamer W, Pollak M: Insulin-like growth factor I and octreotide modulate expression of transforming growth factor β in the mammary gland. J Molec Endocrinol (in press)
63. Ng ST, Zhou J, Wang J, Adesanya OO, LeRoith D, Bondy CA: GH induces primate mammary gland hyperplasia [abstract P1-122]. Proc Endocrine Society 1997, p 165
64. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA: Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 6:297-301, 1997
65. Chen NY, Chen WY, Striker LJ, Striker GE, Kopchick JJ: Co-expression of bovine growth hormone (GH) and human GH antagonist genes in transgenic mice. Endocrinol 138:851-854, 1997
66. Ruan W, Knapp J, Chen W, Kopchick JJ, Kleinberg DL: Mammary gland development is impaired in transgenic mice overexpressing a bovine growth hormone antagonist [abstract P1-121]. Proc Endocrine Society 1997, p 165
67. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM: Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinol 137:321-330, 1995
68. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF: Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 72:1189-1193, 1995
69. Sinha YN, Vlahakis G, VanderLaan WP: Serum, pituitary and urine concentrations for prolactin and growth hormone in eight strains of mice with varying incidence of mammary tumours. Int J Cancer 24:430-437, 1979
70. Sinha YN, Salocks CB, VanderLaan WP: Prolactin and growth hormone levels in different inbred strains of mice: patterns in association with estrous cycle, time of day, and perphenazine stimulation. Endocrinol 97:1112-1122, 1975
71. Juul A, Dalgaard P, Blum WF, et al: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 80:2534-2542, 1995
72. Bruning PF, Van Doom J, Bonfrer JMG, Van Noord PAH, Korse CM, Linders TC, Hart AA: Int J Cancer 62:266-270, 1995
73. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentration in human breast cancer. Eur J Cancer 29A:492-497, 1993
74. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud D, Deroo B, Rosner B, Speizer FE, Pollak M: A prospective assessment of plasma insulin-like growth factor levels in breast cancer risk. Proc Soc Epidemiol Res 1997, abstract #286